All In Biotech

Drug Trial Radar · NCT06195228

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jan 1, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking Union Medical College Hospital; Shanxi Province Cancer Hospital; Henan Cancer Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Zhejiang Cancer Hospital; The Affiliated Hospital of Inner Mongolia Medical University; Ruijin Hospital; Fujian Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shanghai 6th People's Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Shanghai 10th People's Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Changhai Hospital; Tianjin Medical University Cancer Institute and Hospital; Jiangsu Cancer Institute & Hospital; The First Affiliated Hospital of Anhui University of Chinese Medicine; Hunan Provincial People's Hospital; Dalian Friendship Hospital Affiliated to Dalian Medical University; The Third Affiliated Hospital of Soochow University; Sun Yat-sen University; Liaoning Cancer Hospital & Institute; Sir Run Run Shaw Hospital
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

Conditions

  • Advanced Thyroid Cancer Patients Who Received Target Therapy

Interventions

  • dabrafenib plus trametinib with or without PD-1 antibodyDrug

    advanced thyroid cancer patients who harbor BRAF V600E mutation

  • entrectinib or larotrectinib with or without anti-PD-1 antibdoyDrug

    advanced thyroid cancer patients who harbor NTRK mutation

  • pralsetinib or selpercatinib with or without anti-PD-1 antibdoyDrug

    advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

  • anlotinib or anlotinib plus anti-PD-1 antibodyDrug

    For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

  • lenvatinib plus anti-PD-1 antibodyDrug

    Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

  • Other Targets: precise treatment based on the targetDrug

    Advanced thyroid cancer patients who had other treatment targets not included above

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR)Time frame: up to approximately 3 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Peking union medical college hospital

    Beijing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Caixia Liu

    Hohhot, Inner Mongolia, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Shanxi, Taiyuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.